RESEARCH ARTICLE

Dengue-specific serotype related to clinical severity during the 2012/2013 epidemic in centre of Brazil

Benigno A. M. Rocha1,3*, Adriana O. Guilarde1, Angela F. L. T. Argolo1, Marianna Peres Tassara1, Lucimeire A. da Silveira1, Isabela C. Junqueira1, Marília D. Turchi1, Valéria C. R. Féres2 and Celina M. T. Martelli1

Abstract

Multilingual abstracts: Please see Additional file 1 for translations of the abstract into the five official working languages of the United Nations.

Background: Currently, in Brazil, there is a co-circulation of the four dengue (DENV-1 to DENV-4) serotypes. This study aimed to assess whether different serotypes and antibody response patterns were associated with the severity of the disease during a dengue outbreak, which occurred in 2012/2013 in centre of Brazil.

Methods: We conducted a prospective study with 452 patients with laboratory confirmed dengue in central Brazil, from January 2012 to July 2013. The clinical outcome was the severity of cases: dengue, dengue with warning signs, and severe dengue. The patients were evaluated at three different moments. Blood sampling for laboratory testing and confirmatory tests for dengue infection were performed. We performed a multinomial analysis considering the three categories of the dependent variable, as outlined above. The odds ratios (ORs) were calculated. A multinomial logistic regression model was applied for variables with a P-value <0.20. Statistical analysis was performed with STATA 12.0 software.

Results: Four hundred fifty-two patients (452/632, 71.5%) were diagnosed with dengue. The dengue virus (DENV) serotypes were identified in 243 cases. DENV-4 was detected in 135 patients (55.6%), DENV-1 in 91 (37.4%), DENV-3 in 13 (5.3%), and DENV-2 in 4 (1.6%). Patients with the DENV-1 serotype were more prone to present with several clinical and laboratory features as compared with DENV-4 patients, including spontaneous bleeding (P = 0.03), intense abdominal pain (P = 0.004), neurological symptoms (P = 0.09), and thrombocytopenia (P = 0.01). Secondary infection was more predominant among DENV-4 cases (80.0%) compared with DENV-1 cases (62.3%) (P = 0.03). The univariate analysis showed that females (OR = 2.12; 95% CI: 1.44–3.13; P < 0.01) had a higher risk of having dengue with warning signs. The multinomial analysis showed that severe dengue cases with secondary infection had an adjusted OR of 2.80 (95% CI: 0.78–10.00; P = 0.113) as compared with dengue fever with primary infection when adjusted for age and sex.

Conclusion: The current data show that 5.8% of patients recruited for treatment in healthcare centres and hospitals during the study period had severe dengue. DENV-4 was the predominant serotype, followed by DENV-1, in a large outbreak of dengue in central Brazil. Our findings contribute to the understanding of clinical differences and immune status related to the serotypes DENV-1 and DENV-4 in central of Brazil.

Keywords: Dengue, Secondary infection, Severe dengue, Dengue type 4, Brazil

* Correspondence: benigno.rocha@gmail.com
1 Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil
2 School of Nursing, State University of Goiás, Ceres, Brazil

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The etiologic agents of dengue fever and dengue hemorrhagic fever (DF/DHF) are four serotypes: dengue virus (DENV)-1, DENV-2, DENV-3, and DENV-4, part of the dengue complex of the genus Flavivirus [1]. Dengue is a vector-borne viral disease considered to be a global public health issue due to an increasing incidence and its potential to cause epidemics and/or continuous viral circulation in most urban areas in tropical and subtropical regions of the world. In 2010, approximately 390 million dengue-infected individuals and 20,000 deaths were estimated worldwide [2–4].

In Brazil, dengue has been reported yearly since 1986 being widespread from the Atlantic coastal area to other Brazilian macroregions. In 2000, 60% of the dengue cases reported in South America occurred in Brazil [5]. The Brazilian Surveillance System registered at least four dengue epidemics in 2002, 2008, 2010, and 2013, with a predominance with a predominance of the serotypes DENV-3, DENV-2, DENV-1 and DENV-4 in each year, respectively. Currently there is a co-circulation of the four dengue serotypes after DENV-4 was reintroduced in 2010 [6–9].

Dengue presents with a range of symptoms, ranging from asymptomatic through to mild infection to severe illness with life-threatening outcomes. According to the disease progression, there are three clinical phases: the initial febrile phase from 1 to 3 days after the onset of symptoms, followed by the critical phase (4–7 days), and recovery or death. The majority of symptomatic cases progress to DF, considered to be the mild form of the disease.

Clinical classification of dengue has been a matter of extensive discussion in literature [10–15]. The current classification reflects the severity of the clinical features namely DF, dengue with warning signs (DwS), and severe dengue (SD). It has been adopted by the World Health Organization (WHO) and the Brazilian Ministry of Health to guide clinical management [2, 16, 17]. The potential for increasing vascular permeability is the hallmark of severe disease progression [2, 18–20]. Other specific organ involvement such as skin, eye, musculoskeletal system, gastrointestinal tract, liver, kidney and genitourinary tract, heart, and respiratory system are part of the dengue clinical presentation [21–23].

As the four serotypes are considered antigenically related but distinct, the previous immune status of the infected individuals plays an important role in disease progression [24]. In fact, several potential individual risk factors are implicated in dengue severity such as age, gender, immune status related to previous heterologous DENV infection, and co-morbidities, among others [24–28]. Most of the current literature is from Southeast Asia, where the DENV has been circulating for longer time (several decades). In this sense, there is a greater opportunity for research due to the distinct epidemiologic scenarios related to virus circulation and the immunity of the population in many endemic regions [29–32].

In a previous study, we explored the effects of viremic levels of type of infection, primary and secondary, in relation to the severity of the disease in the adult population during a DENV-3 epidemic in early 2000 in central of Brazil [21]. Here, we present a clinical cohort of dengue patients recruited during a DENV-4 outbreak in 2013, which had the largest reported number of incident cases (2233 suspected cases per 100,000 inhabitants) at state level (Goiás, central Brazil) [33, 34]. This was the first time that a simultaneous co-circulation of the four dengue serotypes was detected regionally. This scenario represents an opportunity to explore the immune status of the population, serotypes, and other potential risk factors related to severe disease progression.

The aim of the current study was to assess whether different serotypes and antibody response patterns were associated with the severity of the disease during a dengue outbreak in 2012/2013 in central of Brazil.

Methods

Study design and setting

We recruited 632 clinically suspected dengue cases, out which 452 (71.5%) were laboratory confirmed dengue cases. We conducted a prospective study of these laboratory confirmed dengue patients recruited at three healthcare units and four hospitals in the city of Goiânia (1.4 million inhabitants; Instituto Brasileiro de Geografia e Estatística, 2013), central Brazil, from January 2012 through to July 2013. We recruited patients who attended dengue reference centres established by the Secretariat of Health to deal with the referral of patients during the dengue outbreak in a timely manner. All recruitment sites had clinical expertise and operational capability to provide day healthcare monitoring and intravenous fluid replacement for suspected dengue cases (see Additional file 2).

The study site is a dengue endemic region where dengue incidence peaks during the rainy season (December to March). The dengue virus circulating in this region since 1994, when the official surveillance system detected DENV-1 serotype. During the next two decades, other dengue serotypes were introduced regionally according to the following temporal sequence: DENV-2 (1998), DENV-3 (2002), and DENV-4 (2011). Currently, the four dengue serotypes co-circulate in central Brazil [6, 34, 35]. The incidence of dengue disease was approximately 4500 cases per 100,000 inhabitants in the study setting in 2013. This figure is the highest rate of incidence since dengue was detected in the region, in 1994.
Eligibility criteria and follow-up procedures
Inclusion criteria were laboratory confirmed dengue cases. The virologic and serologic tests for dengue diagnosis were: NS1 antigen positive test and/or detection of serotypes by multiplex polymerase chain reaction (PCR) and/or immunoglobulin M (IgM) serologic positive result by antibody capture enzyme-linked immunosorbent assay (MAC-ELISA).

Exclusion criteria were clinically suspected dengue cases with communication impairment, residents living outside city boundaries, and those with restrictions to comply with follow-up procedures. We also excluded outpatients who did not remain in health facilities for clinical management or monitoring.

Independently of this study protocol, local clinicians were responsible for all management decisions relating to routine health attendance, following the official guidelines [16].

Clinical outcome
The clinical outcome was the severity of dengue cases defined as DF, DwS, or SD [2]. Two infectious disease doctors classified the dengue cases at the end of the follow-up period.

Screening procedures at baseline
We screened patients with clinically suspected dengue independently of their age. We examined outpatients who were receiving intravenous fluid replacement and hospitalized patients. After informed consent was given, trained researchers obtained demographic information and clinical history, and performed medical examinations using standard case report forms. In addition, we collected an initial blood sample for diagnostic laboratory confirmation (t1).

Follow-up
Follow-up visits were scheduled: during the early convalescent phase ≥7 days after the onset of symptoms (t2); and late convalescent phase at 30–45 days after the onset of symptoms (t3). In addition to the clinical examination, we collected blood samples for dengue monitoring, adhering to the same intervals.

For outpatients, the duration of follow-up was the time lag between the first and last blood collections (t2 or t3) performed during the convalescent phase of the disease. The duration of follow-up for hospitalized patients was defined as the period from the first medical visit to either the discharge date or death.

Data collection
We collected sociodemographic characteristics, such as age, sex, socioeconomic status, education, previous dengue episodes, and key warning signs of illness (e.g., hypotension, intense abdominal pain, and significant bleeding), from the patients.

Dengue classification
We used the current dengue classification guidelines recommended by the Dengue Control Program (Brazilian Ministry of Health, 2009), with the recommended WHO classification [2], as:

- DF: The disease may manifest as a nonspecific febrile syndrome including the presence of acute febrile illness and two of the following symptoms: headache, retro-orbital pain, myalgia, arthralgia, rash, or hemorrhagic manifestations.
- DwS: The patient may present with persistent and severe abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, altered mental status, hepatomegaly, and progressive increase in hematocrit.
- SD: Defined by one or more of the following: (i) shock from plasma leakage, fluid accumulation with respiratory distress, or both, (ii) severe bleeding as evaluated by a clinician, or (iii) severe organ involvement; liver: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1000; central nervous system: impaired consciousness; and injury heart and other organs.

Definition of variables
The first seven days after the onset of symptoms denote the acute phase of illness. We defined illness “day 1” as the day of the onset of symptoms. Patients receiving day care were those patients who stayed in the hospital for intravenous fluid replacement for 24 h. Ambulatory patients were patients who attended ambulatory care units and required clinical monitoring and/or intravenous fluid replacement for <24 h.

Laboratory procedures
Blood samples (10 ml) were collected at the initial clinical visit and at follow-up visits. Samples were prepared and sera were cryopreserved according to biosafety guidelines in freezers at −20 °C for serological tests and −80 °C for molecular tests, at the research centre (Laboratory of Molecular Biology and Immunology of Infectious Diseases) of the Institute of Tropical Pathology and Public Health, Federal University of Goiás, central Brazil.

During the baseline and follow-up visits, unspecific laboratory tests were also performed for all eligible patients, including hematocrit, platelet, AST, ALT, and albumin. The reference values for normality were a serum AST level of 50 U/L, a serum ALT level of 41 U/L, and an albumin level of 3.5–5.0 g/dl. Tests were performed at the Rômulo Rocha Laboratory, Faculty of Pharmacy, Federal University of Goiás, central Brazil.
University of Goiás, independently of the laboratory routine procedures followed at the healthcare units.

**Serological tests**
Acute and convalescent-paired sera were tested using the Dengue IgM Capture ELISA (Panbio®, Brisbane, Australia) and Dengue IgG Indirect ELISA (Panbio®, Brisbane, Australia) commercial kits. A NS1 antigen test was performed at baseline (Platelia™, Bio-Rad, California, USA). All tests were conducted according to the manufacturers’ instructions.

**Molecular tests**
The serotypes were identified by protocol, which includes viral RNA extraction using the QiAamp® Viral RNA Mini Kit (QIAGEN Inc., Germantown, MD, EUA). The complementary DNA (cDNA) was obtained by reverse transcription (RT) at 40 °C for 60 min with 10 μL of viral RNA and a mix containing 10 mL random primer and 50 U/μL reverse transcriptase (Applied Biosystems™ High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems, MA, USA).

The viral typing was performed by cDNA amplification using consensus primers (D1 and D2) for the four serotypes of DENV, the complementary sequences of the genes encoding the C and prM proteins. For the amplification of viral RNA the thermocycler Swift™ Maxi Thermal Cycler (ESCO Technologies, OR, USA) was used. Then, the semi-nested specific primers TS1, TS2, TS3, and TS4 were used to detect each serotype of DENV, from 1 to 4 Lanciotti et al. [36]. The bands were visualized on 1.2% agarose gel using a transilluminator (UV Transilluminator, MUV Major Science, CA US).

A primary infection was defined by detecting IgM antibodies and/or nucleic acid and/or antigen NS1 in acute serum samples and seroconversion of IgG in the convalescent phase. A secondary infection was defined by detecting IgG antibodies in acute serum samples of patients with laboratory confirmed dengue.

**Data analysis**
Initially, we applied descriptive statistics to assess the distribution of the variables in order to characterize the study population. The chi-square test and t-test were applied in order to verify statistical differences between categorical or continuous variables, respectively. We performed a multinomial analysis taking into account the three categories of the dependent variables (DF, DwS, SD) to calculate the association between the outcomes and the independent variables, considering DF as the reference. The odds ratios (ORs), with their respective 95% confidence intervals (95% CIs), and the P-values (chi-square test) were calculated. Variables that presented with a P < 0.20 in association with the outcome were eligible for the multivariate analysis. We applied a multinomial logistic regression model to adjust ORs for sex and age as a continuous variable. The software used for the multinomial analysis was STATA version 12.0 (StataCorp LLC, TE, USA).

---

**Fig. 1** Flowchart showing suspected dengue cases recruited for the study
Ethical considerations
This study was approved by the Ethics Committee on Research of the Aggeu Magalhães Research Center (FIOCRUZ-PE) (No. 24/11) and the review board of each institution. Patients gave informed consent or when less than 18 years old this was given by the parents or guardians.

Results
Of the 632 symptomatic dengue cases clinically and laboratorially screened at baseline, 452 (71.5%) were diagnosed as dengue confirmed by specific serology and/or viral detection (see Fig. 1). Table 1 presents the clinical and epidemiological data according to case ascertainment. In both groups (dengue confirmed and symptomatic cases), the majority of patients (~ 80%) were adult and approximately half were females. Approximately 75% of the patients were recruited in ambulatory settings and reported previous medical visits during the acute phase of the disease. Adult population comorbidity was similar between the groups.

Table 1

| Characteristics          | Laboratory confirmed dengue cases (%) | Unconfirmed dengue cases (%) | \( \chi^2 \) |
|--------------------------|--------------------------------------|----------------------------|----------|
| Suspected cases dengue   | 452 (71.5)                           | 180 (28.5)                 | –        |
| Mean age (dp)            | 35.7 (17.5)                          | 34.8 (16.6)                | 0.546    |
| Age group (years)        |                                      |                            |          |
| \( \leq 1 \)             | 2 (0.4)                              | 3 (1.7)                    | 0.288    |
| 2–15                     | 48 (10.6)                            | 15 (8.3)                   | 0.371    |
| 16–39                    | 233 (51.5)                           | 100 (55.6)                 | 0.320    |
| 40–59                    | 118 (26.1)                           | 44 (24.4)                  | 0.629    |
| \( \geq 60 \)            | 51 (11.3)                            | 18 (10.0)                  | 0.619    |
| Gender                   |                                      |                            |          |
| Female                   | 235 (52.0)                           | 88 (48.9)                  | 0.481    |
| Male                     | 217 (48.0)                           | 92 (51.1)                  | 0.481    |
| Health care setting      |                                      |                            |          |
| Ambulatory               | 340 (75.2)                           | 126 (70.0)                 | 0.178    |
| Hospital                 | 112 (24.8)                           | 54 (30.0)                  | 0.178    |
| Previous medical visit   | 142 (31.4)                           | 64 (31.9)                  | 0.316    |
| Comorbidity\( ^d \)      | 115 (25.4)                           | 48 (29.4)                  | 0.751    |
| Hypertension             | 82 (18.1)                            | 30 (16.7)                  | 0.661    |
| Diabetes                 | 25 (5.5)                             | 11 (6.1)                   | 0.776    |
| Asthma                   | 14 (3.1)                             | 8 (4.4)                    | 0.404    |
| Chronic renal failure    | 8 (1.8)                              | 2 (1.1)                    | 0.549    |
| Others\( ^c \)           | 15 (3.3)                             | 11 (7.2)                   | 0.669    |
| Deaths                   | 1 (0.2)                              | 1 (0.6)                    | 0.487    |

\(^a\) Laboratory confirmed dengue cases were positive by at least one of the test (RT-PCR and/or NS1 and/or IgM).

\(^b\) \( \chi^2 \) test

\(^c\) Considering 540 adult patient (\( \geq 18 \) years).

\(^d\) Lupus erythematosus; cancer; AIDS; transplantation and hepatitis B or C.
higher frequency of primary infection (39.4% versus 22% among the adult population), which was a statistically significant difference.

Of the 452 patients surveyed, they were classified as Dengue Fever 188 (41.6%), Dengue with Alert Signs 238 (52.6%) and Severe Dengue 26 (5.8%). The DENV serotypes were identified in 243 (53.8%) out of 452 patients, tested by RT-PCR. DENV-4 was the predominant serotype, detected in 135 (55.6%) patients, followed by DENV-1 in 91 (37.4%) patients. DENV-3 and DENV-2 were detected in 13 (5.3%) and 4 (1.6%) patients, respectively (see Table 3).

Among the 26 cases of SD, nine had the DENV serotypes identified and all were infected with DENV-1; comprising five males and four females, aged seven to 57 years (median: 43 years). Descriptive analyses by serotype showed similar age and gender distributions of the patients infected with serotypes DENV-1 and DENV-4; the majority of patients were adults and approximately half were females. Each serotype included a large range of clinical forms and biological variations (data not shown).

Patients with a detectable DENV-1 serotype were more prone to present with several clinical and laboratory features as compared with DENV-4 patients, including spontaneous bleeding (DENV-1: 33.0% versus DENV-4: 20.0%; \( P = 0.03 \)); intense abdominal pain (DENV-1: 29.7% versus DENV-4: 14.1%; \( P = 0.004 \)); neurological symptoms (DENV-1: 6.7% versus DENV-4: 2.2%; \( P = 0.09 \)); and thrombocytopenia (DENV-1: 33.7% versus DENV-4: 18.2%; \( P = 0.01 \)). The immune status measured by primary or secondary infections were available for 202 patients (DENV-1 or DENV-4). Secondary infection was more predominant among DENV-4 cases (80.0%) compared with DENV-1 cases (62.3%), a statistically significant difference between the serotypes (\( P = 0.03 \)).

Table 4 presents the results of the multinomial analysis (the association between the antibody response pattern,
serotype, and severity of disease taking DF as a reference). The univariate analysis showed that females were at a higher risk of having DwS \((OR = 2.12; 95\% CI: 1.44–3.13; P < 0.01)\) in comparison with DF patients. Females classified as having SD did not differ from the reference. Adult patients \((\geq 15 \text{ years old})\) had an \(OR\) of \(0.53\) \((95\% CI: 0.26–1.08; P = 0.082)\) compared to children with DF. Comorbidity was not associated with the severity of the disease. Patients classified as having DwS and that mounted secondary infection were found to be not at risk \((OR = 1.03; 95\% CI: 0.66–1.60; P = 0.890)\) compared with DF patients with primary infection. In addition, SD cases with secondary infection had an \(OR\) of \(2.63\) \((95\% CI: 0.74–9.30; P = 0.134)\). Results of DENV-1 and DENV-4 were presented for DwS versus FD, as few cases of DENV-2 and DENV-3 were detected in this

### Table 2: Clinical and laboratory findings of confirmed dengue patients stratified by age-group

| Features | < 15 years | ≥ 15 years | \(P^a\) |
|----------|------------|------------|--------|
| **Signs and symptoms reported or observed during recruitment** | | | |
| Age, years - median (min-max) | 10.1 (0–14) | 38.4 (15–83) | – |
| Female sex | 25 (59.5) | 210 (51.2) | 0.305 |
| Days of illness - median (min-max) | 4 (2–8) | 5 (1–13) | 0.535^9 |
| Headache | 36 (85.7) | 335 (81.7) | 0.519 |
| Prostration | 41 (97.6) | 373 (91.0) | 0.139 |
| Rash | 29 (69.0) | 269 (65.6) | 0.654 |
| Vomit | 23 (54.8) | 175 (42.7) | 0.133 |
| **Signs and symptoms reported or observed during the course of the disease** | | | |
| Spontaneous bleeding | 20 (47.6) | 109 (26.6) | 0.004 |
| Gastrointestinal bleeding | 3 (7.1) | 22 (5.4) | 0.631 |
| Neurological alterations | 1 (2.4) | 24 (5.9) | 0.346 |
| Breathing difficulties | 0 | 51 (12.4) | 0.015 |
| Icterus | 1 (2.4) | 17 (4.1) | 0.576 |
| Intense abdominal pain | 12 (28.6) | 66 (16.1) | 0.042 |
| Hepatomegaly | 3 (11.1) | 24 (5.9) | 0.737 |
| Effusions and Ascites | 4 (9.5) | 8 (2.0) | 0.004 |
| **Main laboratory results during the course of the disease** | | | |
| Hemoconcentration^b | 12 (29.3) | 77 (19.6) | 0.146 |
| Leukopenia (< 4000 cel/ml)^c | 20 (50.0) | 230 (58.4) | 0.223 |
| Thrombocytopenia (< 100,000 cel/ml)^d | 9 (22.0) | 123 (31.1) | 0.307 |
| AST (> 1000)^e | 0 | 0 | – |
| ALT (> 1000)^f | 0 | 0 | – |
| **Clinical classification** | | | |
| Dengue Fever | 12 (28.6) | 176 (42.9) | 0.075 |
| Dengue with Warning Signs | 27 (64.3) | 211 (51.5) | 0.103 |
| Severe Dengue | 3 (7.1) | 23 (5.6) | 0.307 |
| **Antibody response pattern^h** | | | |
| Primary | 13 (39.4) | 67 (22.7) | 0.034 |
| Secondary | 20 (60.6) | 228 (77.3) | 0.034 |

---

^a\(\chi^2\) test  
^b323 results available  
^c432 results available  
^d433 results available  
^e416 results available  
^f415 results available  
^gMann-Whitney Test  
^h328 analysed
study. The multinomial analysis showed that SD cases with secondary infection had an adjusted OR of 2.80 (95% CI: 0.78–10.00; \( P = 0.113 \)) compared with DF patients with primary infection, when adjusted for age and sex (see Table 5).

### Table 3: Clinical and epidemiological characteristics of 452 laboratory confirmed dengue cases, Central Brazil, 2012 and 2013

| Parameters               | Dengue Fever \( N = 188 \) (%) | Dengue with Warning Signs \( N = 238 \) (%) | Severe Dengue \( N = 26 \) (%) |
|--------------------------|---------------------------------|---------------------------------------------|-------------------------------|
| Gender                   |                                 |                                             |                               |
| Female                   | 78 (41.5)                       | 143 (60.1)                                  | 14 (53.8)                     |
| Age group (years)        |                                 |                                             |                               |
| < 1                      | 1 (0.5)                         | 1 (0.5)                                     | 0                             |
| 2 a 14                   | 11 (5.8)                        | 26 (10.9)                                   | 3 (11.5)                      |
| 15 a 39                  | 108 (57.5)                      | 123 (51.6)                                  | 10 (38.5)                     |
| 40 a 59                  | 44 (23.4)                       | 63 (26.5)                                   | 11 (42.3)                     |
| ≥ 60                     | 24 (12.8)                       | 25 (10.5)                                   | 2 (7.7)                       |
| Comorbidity              | 46 (24.5)                       | 60 (25.2)                                   | 9 (34.6)                      |
| Antibody response pattern|                                 |                                             |                               |
| Primary                  | 38 (27.3)                       | 40 (23.0)                                   | 2 (13.3)                      |
| Secondary                | 101 (72.7)                      | 134 (77.0)                                  | 13 (86.7)                     |
| Serotypes\(^a\)          |                                 |                                             |                               |
| DENV-1                   | 35 (18.6)                       | 47 (19.7)                                   | 9 (34.6)                      |
| DENV-2                   | 2 (1.1)                         | 2 (0.8)                                     | 0                             |
| DENV-3                   | 3 (1.6)                         | 10 (4.2)                                    | 0                             |
| DENV-4                   | 63 (33.5)                       | 72 (30.3)                                   | 0                             |
| Undetectable             | 75 (39.9)                       | 98 (41.2)                                   | 15 (57.7)                     |
| Not done                 | 10 (5.3)                        | 9 (3.8)                                     | 2 (7.7)                       |

\(^a\)Serotypes determined by reverse-transcription polymerase chain reaction (RT-PCR)

### Table 4: Multinomial analysis of the association between antibody response pattern, serotype and severity of dengue disease as outcome

| Parameters               | Dengue Fever \( N = 188 \) (%) | Dengue with Warning Signs \( N = 238 \) (%) | P-value | Severe Dengue \( N = 26 \) (%) | OR (95% CI) | P-value |
|--------------------------|---------------------------------|---------------------------------------------|---------|-------------------------------|-------------|---------|
| Gender                   |                                 |                                             |         |                               |             |         |
| Female                   | 78 (41.5)                       | 143 (60.1)                                  | 0.000   | 14 (53.8)                     | 1.64 (0.72–3.75) | 0.236   |
| Age group (years)        |                                 |                                             |         |                               |             |         |
| < 15                     | 12 (6.4)                        | 27 (11.3)                                   | Reference | 3 (11.5)                     | Reference   | –       |
| ≥ 15                     | 176 (93.6)                      | 211 (88.7)                                  | 0.53 (0.26–1.08) | 0.082 | 23 (88.5) | 0.52 (0.14–1.99) | 0.342 |
| Comorbidity              | 46 (24.5)                       | 60 (25.2)                                   | 1.04 (0.67–1.62) | 0.860 | 9 (34.6)  | 1.63 (0.68–3.92) | 0.271 |
| Antibody response pattern\(^a\) |                                 |                                             |         |                               |             |         |
| Primary                  | 53 (28.2)                       | 62 (26.1)                                   | Reference | 3 (11.5)                     | Reference   | –       |
| Secondary                | 121 (64.4)                      | 146 (61.3)                                  | 1.03 (0.66–1.60) | 0.890 | 18 (69.2) | 2.63 (0.74–9.30) | 0.134 |
| Serotype\(^b\)           |                                 |                                             |         |                               |             |         |
| DENV-1                   | 35 (19.7)                       | 47 (19.7)                                   | Reference | –                        | NA          | –       |
| DENV-4                   | 63 (35.4)                       | 72 (30.3)                                   | 0.85 (0.49–1.48) | 0.568 | 0 (NA)     | NA          | –       |

\(^a\)49 patients not evaluated

\(^b\)Serotypes determined by reverse-transcription polymerase chain reaction (RT-PCR) and 226 patients not evaluated

### Discussion

Our results show differences in the clinical features of dengue patients infected during a large DENV-4 outbreak in central Brazil. Children presented higher frequencies of several warning signs of disease severity...
such as spontaneous bleeding, intensive abdominal pain, and neurological symptoms when compared to adults. Secondary infections were more prone to occur in the adult population, however, more than 60% of the children and almost 80% of the adult patients in this study were found to have a previous dengue infection, highlighting the high DENV circulation in the region.

Few studies have compared clinical features and laboratory abnormalities in the pediatric age group and adults in Brazil [37, 38]. A study conducted in the same region in 2005 showed that secondary infection was not a predictor of severe clinical manifestation in adults infected with the DENV-4 serotype [21].

In a prospective clinical study conducted in the same city in 2000, we found that mild cases of dengue were predominant among adults [21]. In this study, we classified the majority of the pediatric and adult patients as having DwS, followed by DF, and a few cases of SD. This distribution reflects the clinical characteristics of dengue patients treated at reference day clinics and hospitals during the 2012/2013 epidemic. It does not resemble the entire cohort of dengue patients, as most of the cases were milder cases classified as DF, as according to the surveillance system (SINAN, 2012/2013).

It is important to note that all patients classified as having SD were infected with DENV-1 and none were infected with DENV-4. However, we are aware that our sample size relating to the severe form of the disease is too small to draw a conclusion. Interestingly, the historical data outlined by Hastead in the early decades of dengue epidemics regarding differences in clinical manifestations of DENV-1 and DENV-4 serotypes in Southeast Asia similarly describe DENV-1 as being more prone to cause severe cases as compared with DENV-4 [39].

In our study, we found a high percentage of undetectable viremia among severe cases. Dengue patients may progress to severe disease during the defervescence period, which is the period of hospital admission and recruitment that is beyond the viremic period [21]. We are aware that this could represent a potential selection bias in the recruitment of severe cases.

One of the strengths of this study was the recruitment of dengue patients approximately two years after the introduction of the DENV-4 serotype in central Brazil. In this context, it is likely that the majority of the population in the study area was naïve to DENV-4, which explains the current outbreak with the predominance of the DENV-4 circulation. In fact, DENV-4 had been previously isolated in nine patients in the neighbouring state of Mato Grosso do Sul in 2012. The authors had warned about the potential for outbreaks due to the introduction of the DENV-4 serotype in a susceptible population to this serotype in central Brazil [40].

Another strength of our study is that we recruited patients in several ambulatories and hospital settings within the region. However, our study population included only patients living in one city and the results may not be generalizable to rural areas or other regions of the country.

Comparison of clinical manifestations, antibody response patterns, and severity of the disease were restricted to the DENV-4 and DENV-1 serotypes, as few patients had detectable DENV-2 or DENV-3 serotypes in this study. These findings are concordant with the official laboratory system in charge of DENV surveillance regionally. It is interesting that the DENV-2 serotype had not been predominantly registered by the viral surveillance system in the last two decades in the study area [35]. We are aware that according to the period when the blood samples for serological tests (IgM or IgG) were collected, this may yield negative or positive results, which could lead to the misclassification of primary and secondary infections.

**Conclusions**

In summary, the present study shows the incidence of SD among pediatric and adult patients in the first registered DENV-4 outbreak in central Brazil. To our knowledge, this is the first prospective clinical study to compare DENV-1 and DENV-4 patients in relation to antibody response patterns and severity of the disease. Our findings contribute to the understanding of clinical differences and immune status related to the serotypes DENV-1 and DENV-4 in central Brazil.

**Additional file**

- **Additional file 1:** Multilingual abstracts in the five official working languages of the United Nations. (PDF 644 kb)
- **Additional file 2:** Association between clinical or laboratory markers and dengue serotypes, Central Brazil, 2012 and 2013. (DOCX 13 kb)
Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; cDNA: Complementary DNA; Co.: Confidence interval; CNS: Central nervous system; DENV: Dengue virus; DENV: Virus dengue; DF: Dengue fever; DdF: Dengue hemorrhagic dengue fever; DwC: Dengue with warning signs; ELISA: Enzyme-linked immunosorbent assay; IBGE: Instituto Brasileiro de Geografia e Estatística; Ig: Immunoglobulin; IgG: Immunoglobulin G; IgM: Immunoglobulin M; NS1: Non-structural protein-1; OR: Odds ratio; PCR: Polymerase chain reaction; RNA: Ribonucleic acid; RT: Reverse transcription; RT-PCR: Reverse transcription-polymerase chain reaction; SD: Severe dengue; STATA: Data analysis and statistical software; WHO: World Health Organization

Acknowledgements
We would like to thank the State Health Department of Goiás, the Municipal Health Department of Goiânia for its collaboration, and the cooperation of the employees of the health units participating in the study.

We thank the director and staff of the participating hospitals and the Secretariat of Health. We also thank the patients for their collaboration and generosity.

Funding
This study was funded by the National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq); and the Foundation for the State of Goiás Research (FAPEG).

Availability of data and materials
The datasets collected and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions
BAMR conducted the molecular biology tests, participated in the data analysis, and wrote the paper. AOG held the patients’ clinical classification (FD, DwS e DwC) and contributed to the writing of the paper. AETF participated in the data collection and assisted in the laboratory exams. MPT participated in the data collection and conducted the patients’ clinical classification. LAS coordinated the fieldwork and assisted with the laboratory exams. ICI participated in the data collection and performed the laboratory exams. MDT assisted in the fieldwork and assisted with the laboratory exams. ICJ participated in the data collection and assisted in the laboratory exams. MPT participated in the data analysis, and wrote the paper. All authors approve the paper for publication.

Authors’ information
BAMR has a PhD in Tropical Medicine and Public Health with an emphasis on epidemiology from the Institute of Tropical Pathology and Public Health of the Federal University of Goiás. He is also a public health professor at the State University of Goiás. Visit this link to see his CV: http://lattes.cnpq.br/70491930317115490.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was approved by the Ethics Committee on Research of the Aggeu Magalhães Research Center (FIOCRUZ-PE) (No. 24/11) and the review boards of each institution. Patients gave informed consent or when less than 18 years old this was given by the parents or guardians.

Trial registration number
This study is not a clinical trial. It is a prospective observational study and therefore did not need to be registered.

Author details
1Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil. 2Faculty of Pharmacy, Federal University of Goiás, Goiânia, Brazil. 3School of Nursing, State University of Goiás, Ceres, Brazil.

References
1. Gubler DJ. Dengue viruses: their evolution, history and emergence as a global public health problem. In: Duane J, Gubler, Eng Eong Ooi, Subhash Vasudevan JF, editor. Dengue and dengue hemorrhagic fever. 2nd ed. London: 2014. p. 1–29.
2. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention, and control. New Edition. Geneva: World Health Organization; 2009.
3. Guzman MG, Halstead SB, Artsob H, Buchy P, Faran J, Gubler DJ, et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010;8:57–16.
4. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7.
5. Brathwaite Dick O, San Martin JL, Montoya RH, del Diego J, Zambrano B, Dayan GH. The history of dengue outbreaks in the Americas. Am J Trop Med Hyg. 2012;87:584–93.
6. Siqueira JB, Martelli CMT, Coelho GE, da R Simplicio AC, Hatch DL. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg Infect Dis. 2005;11:48–53.
7. Teixeira MG, Siqueira JB, Ferreira GLC, Bicks L, Joint G. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7:e2520.
8. Number of Reporter Cases of Dengue and Severe Dengue (SD) in the Americas, by country: Figures for 2014 (to week noted each country). In: Annual cases reported of dengue. PAHO. 2015. http://www2.paho.org/hq/index.php?option=com_topics&view=readall&id=3273&Itemid=68&lang=pt. Accessed 18 Jul 2015.
9. Temporoso JG, Penna GQ, Carmo BH, Coelho GE, do Socorro Silva Azevedo R, Teixeira Nunes MR, et al. Dengue virus serotype 4, Roraima State, Brazil. Emerg Infect Dis. 2011;17:938–40.
10. Gubírez G, Greh L, Pérez MÁ, Elizondo D, Áviles W, Kuan G, et al. Evaluation of the diagnostic utility of the traditional and revised WHO dengue case definitions. PLoS Negl Trop Dis. 2013;7:e2385.
11. Jayaratne SD, Atukorale V, Gomes L, Chang T, Wijesinghe T, Fernando S, et al. Evaluation of the WHO revised criteria for classification of clinical disease severity in adult dengue infection. BMC Res Notes. 2012;5:645.
12. Bandyopadhyay S, Lum LCS, Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Tropical Med Int Health. 2006;11:238–55.
13. Prasad D, Kumar C, Jain A, Kumar R. Accuracy and applicability of the revised WHO classification (2009) of dengue in children seen at a tertiary healthcare facility in northern India. Infection. 2013;41:775–82.
14. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, Rocha C, et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet. 2006;368:170–3.
15. Alexander N, Balmaseda A, Coelho IC, Dimiao E, Hien TH, Hung NT, et al. Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries. Tropical Med Int Health. 2011;16:936–48.
16. BRASIL. Dengue diagnóstico e manejo clínico adulto e criança. 4º ed. Ministério da Saúde; Brasília. 2013. (in Portuguese).
17. BRASIL. Nova classificação de caso de Dengue - OMS. 1º ed. Ministério da saúde; Brasília. 2014. (in Portuguese).
18. dos RFC BM, de A Luna EJ, Braga Júnior LL, de RVB O, LTM R, do S da Silva M, et al. Risk factors associated with death in Brazilian children with severe dengue: a case-control study. Clinics. 2014;69:55.
19. Bhaskar E, Sowmya G, Moorthy S, Sundar V. Prevalence, patterns, and factors associated with bleeding tendencies in dengue. J Infect Dev Ctries. 2015;9:105–10.
20. Trung D the, Wills B. Clinical features of dengue. In: Duane J, Gubler, Eng Eong Ooi, Subhash Vasudevan JF, editor. Dengue and dengue hemorrhagic fever. 2nd ed. London. 2014. p. 115–44.
21. Gubler DJ, Peng JH, Xiang JY, Cui J, Zou Y, He J, et al. Risk factors associated with death in Brazilian children with severe dengue: a case-control study. Clinics. 2014;69:55–60.
22. Dayan GH. The history of dengue outbreaks in the Americas. Am J Trop Med Hyg. 2012;87:584–93.
23. Acute Respiratory Failure and active bleeding are the important fatality predictive.
factors for severe dengue viral infection. Ooi EE, editor. PLoS One. 2014;9:e114499. Public Library of Science.

23. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053–9.

24. Pawitan JA. Dengue virus infection: predictors for severe dengue. Acta Med Indones. 2011;43:129–35.

25. Guzmán MG, Kouri G, Valdés L, Bravo J, Vázquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002;11:223–7.

26. Kalayanarooj S, Nimmannitya S. Is dengue severity related to nutritional status?. Southeast Asian J Trop Med Public Health. 2005. p. 378–84.

27. Lee M-S, Hwang K-P, Chen T-C, Lu P-L, Chen T-P. Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. J Microbiol Immunol Infect. 2006;39:121–9.

28. Martins AC, Pereira TM, Oliart-Guzmán H, Delfino BM, Mantovani SAS, Braha AM, et al. Seroprevalence and seroconversion of dengue and implications for clinical diagnosis in amazonian children. Interdiscip Perspect Infect Dis. 2014;2014:703875.

29. Halstead S. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476–81.

30. Thomas L, Verlaeten O, Cablé A, Kaidornar S, Moravie V, Martial J, et al. Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic. Am J Trop Med Hyg. 2008;78(6):990–8.

31. Rosen L. The Emperor’s new clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg. 1977;26:337–43.

32. Kouri GP, Guzmán MG, Bravo JR. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans R Soc Trop Med Hyg. 1987;81:821–3.

33. Boletim Semanal de Dengue - Goiás 2014: Semana Epidemiológica 1 a 53 (14/12/2013 a 03/01/2015). In: Boletim Semanal de Dengue. Secr. Estadual de Saúde de Goiás; 2015. https://extranet.saude.go.gov.br/public/dengue.html. Accessed 5 Aug 2015. (in Portuguese).

34. Boletim Semanal de Dengue - Goiás 2013. In: Boletim Semanal de Dengue. Secr. Estadual Saúde; 2013. http://www.saude.go.gov.br/index.php?doEditoria=4208. Accessed 9 Aug 2015. (in Portuguese).

35. Feres VCR, Martelli CMT, Turchi MD, Junior JBS, Nogueira RMR, Rocha BAM, et al. Laboratory surveillance of dengue virus in Central Brazil, 1994-2003. J Clin Virol. 2006;37:179–83.

36. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol. 1992;30:545–51.

37. Brito CAA de. Dengue em Recife, Pernambuco: padrões clínicos, epidemiológicos, laboratoriais e facotres de risco associados à forma grave da doença. https://www.arca.fiocruz.br/handle/icict/3908. (2007). Acessede 9 Jul 2014. (in Portuguese).

38. Escoeteguy CC, Pereira AGL, Medronho RDA, Rodrigues CS, Chagas KKF. Diferenças, segundo faixa etária, do perfil clínico-epidemiológico dos casos de dengue grave atendidos no Hospital Federal dos Servidores do Estado, Rio de Janeiro-RJ, Brasil, durante a epidemia de 2008: Epidemiol e Serviços Saúde. 2013;22:67–76. (in Portuguese).

39. Nishiura H, Halstead SB. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis. 2007;195:1007–13.

40. Bertolacci-Rocha LG, da Cunha RV, de Castro Lichs GG, Dal Fabbro MMFJ, Motta-Castro ARC. Introduction of the dengue virus type 4 in the State of Mato Grosso do Sul, Brazil Cad Saude Publica. 2014;30:1789–92.